OBJECTIVES: Approximately 80% of newly diagnosed bladder cancer patients in the UK will be diagnosed with non-invasive bladder cancer (NIBC). The use of Hexvix (hexaminolevulinate) during transurethral resection of the bladder (TURB) results in a higher detection rate and more complete resection when compared to white light cystoscopy (WLC) alone. A decision tree model was developed to assess the budget impact associated with Hexvix. METHODS: The model structure, costs and treatment algorithms were based on the European Association of Urologist (EAU) guidelines, review of the literature and clinical practice in the UK. The model assumes a relative reduction in recurrence for Hexvix when compared to WLC based on data obtained with an unlicensed and less readily taken up fluorescent molecule. Model predictions include cost savings, reductions in procedures and disease-free days (DFD) over a two year time horizon. RESULTS: Of the 12,000 patients diagnosed with bladder cancer in the UK, 9641 were predicted by the model to have NIBC. In these patients, the model predicts an 18% reduction in the number of cystoscopies and 4.3% reduction in TURBs when Hexvix use was compared to WLC. In addition, an increase of 211 106 DFD was predicted over the 2 year time horizon (177,029 in 2410 high risk patients, 14,721 in 2410 medium risk patients and 19,355 in 4821 low risk patients). The model predicts an overall increase in cost of managing these patients of Յ2,769,712 (3.9%) over WLC, and an incremental cost of Յ21.90 per patient per disease-free year. CONCLUSION: Although the quality of life was not modelled the assumed reduction in the number of cystoscopies and TURBS could potentially have a significant impact on the quality of life. The increase in the cost of may be off-set by the improvement to the current regimen.
Paessens B 1 , Berger K 2 , Ihbe-Heffinger A 1 , Mueller-Thomas C 1 , Shlaen M 3 ,Von Schilling C 4 , Bernard R 1 , Peschel C 1 , Schramm W 2 1 Klinikum rechts der Isar der Technischen Universität München, München, Germany, 2 University Hospital of Munich, München, Germany, 3 Medical Economic Research Group (MERG), München, Germany, 4 Klinikum Freising, Freising, Germany OBJECTIVES: To analyse resource use and direct medical cost of sepsis as adverse drug reaction of cancer treatment. Special regard was paid to the use of blood products. METHODS: Prospective observational study in a German academic cancer center (ACC). Consecutive non-small cell lung cancer (NSCLC) and lymphoma patients were enrolled at the start of first or second line (immuno) chemotherapy treatment. Patients receiving high dose chemotherapy were excluded. Sepsis (infection grade 4) was recorded prospectively according to the Common Terminology Criteria for Adverse Events v3.0. Clinical data and resource use at the ACC were collected from pre-planned chart reviews. Direct costs were calculated from ACC perspective. RESULTS: In all, 180 evaluable patients underwent a total of 633 chemotherapy cycles. Seven episodes of sepsis were observed in 7 patients (3.9%). Five of them had malignant lymphoma. Three patients received sepsis treatment at a local hospital and 4 at the ACC. All ACC patients received intravenous antibiotics and diagnostic work-up for infection. Blood components were transfused to 3 patients. Median and range of the number of transfusion units per patient were 6 (4-17), 14 (4-24), 23.5 (14-33) and 24 (4-74) for red blood cells, platelets, fresh frozen plasma and all blood components respectively. 3 of 4 patients were treated at an intensive care unit (ICU) for 9-31 days. Overall median length of stay was 18.5 days. Total cost per episode varied between €8.077 and €67.437. In all episodes basic hotel services and personnel costs were the cost driver (€3.795-35.898), followed by expenses for drugs (€1.489-9.151) and blood products (€0-10.976). CONCLUSION: Health care utilisation and cost of treating one episode of sepsis varied substantially. Transfusion need was heterogeneous but high on average. Further research should compare costs and revenue of highcost-cases in the German DRG system.
